HUGE.CN - FSD Pharma Inc.

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
0.2750
0.0000 (0.00%)
As of 11:36AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.2750
Open0.2800
Bid0.275 x 0
Ask0.280 x 0
Day's Range0.2750 - 0.2800
52 Week Range0.0750 - 0.9400
Volume863,088
Avg. Volume9,863,703
Market Cap377.743M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.002
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • FSD Pharma Provides Update on Operations, Strategy and Leadership
    CNW Group7 days ago

    FSD Pharma Provides Update on Operations, Strategy and Leadership

    TORONTO , Feb. 14, 2019 /CNW/ - FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD"), a licensed producer under the Cannabis Act, today provided a corporate update on operations, strategy and leadership changes. On February 6, 2019 , the Company announced it had implemented changes in leadership and business practices to optimize operations. Accordingly, the Company announced that Dr. Raza Bokhari , Executive Co-Chairman, has been appointed interim Chief Executive Officer of FSD Pharma.

  • GlobeNewswire8 days ago

    CBD Med Research and World Class Extractions Announce Signing of Definitive Agreement

    CBD Med Research Corp. (“CBD”) and World Class Extractions Inc. (“World Class”) are pleased to announce, further to the parties’ press release dated August 15, 2018, the execution of a definitive business combination agreement (the “Combination Agreement”) on February 13, 2019 which, subject to certain conditions and applicable shareholder and regulatory approvals, will result in a reverse takeover of CBD by World Class (the “Proposed Transaction”). The resulting issuer that will exist upon completion of the Proposed Transaction (the “Resulting Issuer) intends to apply to the Canadian Securities Exchange (“CSE”) for approval for listing its common shares on the CSE. The technology allows the extraction of CBD Oil and other related extracts from wet or dried natural plants.

  • FSD Pharma Enters into Supply Agreement with Canntab Therapeutics and World Class Extractions on Organic Hemp Deal
    CNW Group9 days ago

    FSD Pharma Enters into Supply Agreement with Canntab Therapeutics and World Class Extractions on Organic Hemp Deal

    TORONTO , Feb. 12, 2019 /CNW/ - FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD"), a licensed producer under the Cannabis Act, announced today that it has entered into a supply agreement (the "Agreement") with Canntab Therapeutics Ltd. ("Canntab") and World Class Extractions Inc. ("World Class") (the "Purchasers") to purchase hemp flower from Thomas Elcome (the "Supplier"). Pursuant to the agreement, the Purchasers have agreed to buy approximately 1,000 kg of the Supplier's 2018 hemp crop at a purchase price of $100.00 per kg per 1% of CBD extracted from the flower.

  • Market Exclusive10 days ago

    FSD Pharma to Use Pharmastrip Equipment to Make Cannabis-Infused Oral Strips

    FSD Pharma (CSE: HUGE) (OTCQB: FSDDF) made a $1.5-million investment in Pharmastrip Corp. and inked an agreement with the company as part of its plans to produce cannabis products. Under the terms of the agreement, FSD will install Pharmastrip equipment at its facility in Cobourg, Ontario. The company will use the equipment to manufacture organic […]The post FSD Pharma to Use Pharmastrip Equipment to Make Cannabis-Infused Oral Strips appeared first on Market Exclusive.

  • FSD Pharma responds to and corrects misleading Auxly claims
    CNW Group13 days ago

    FSD Pharma responds to and corrects misleading Auxly claims

    FSD Pharma strongly denies that it caused any breaches of the Streaming Agreement relating to its management and staffing obligations or otherwise, and rejects the claim that there are material issues with the infrastructure of its cultivation facility in Cobourg, Ontario . "FSD's Board and management team are focused on taking action to deliver on a strategy that promotes growth and creates shareholder value. As disclosed on Wednesday, February 6 , FSD terminated the Definitive Agreement with Auxly.

  • Business Wire13 days ago

    FSD Pharma Responds to and Corrects Misleading Auxly Claims

    FSD Pharma Inc.(HUGE.CN) (FSDDF) (0K9.F) a licensed producer under the Cannabis Act, responded today to a press release by its former partner, Auxly Cannabis Group Inc. (“Auxly”) to correct misleading claims. FSD Pharma strongly denies that it caused any breaches of the Streaming Agreement relating to its management and staffing obligations or otherwise, and rejects the claim that there are material issues with the infrastructure of its cultivation facility in Cobourg, Ontario. “FSD’s Board and management team are focused on taking action to deliver on a strategy that promotes growth and creates shareholder value.

  • GlobeNewswire14 days ago

    Auxly Announces Termination of FSD Pharma Joint Venture

    Auxly Cannabis Group Inc. (TSX.V - XLY) ("Auxly" or the "Company") today announced the termination of the definitive agreement dated March 3, 2018 (the “Agreement”) between the Company and FV Pharma Inc., a wholly-owned subsidiary of FSD Pharma Inc. (“FSD Pharma”) (CSE:HUGE) governing the joint venture between the parties. The joint venture was formed with the intention of developing a portion of FSD Pharma's cannabis cultivation facility located in Cobourg, Ontario (the “JV Facility”) in mutually agreed staged phases (the “JV Facility Development”).

  • Business Wire14 days ago

    FSD Pharma Signs Collaboration and Profit-Sharing Agreement with Pharmastrip for Production and Delivery of Organic Medical Cannabis Infused in Oral Thin Film Strips

    FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) (“FSD” or the “Company), a licensed producer under the Cannabis Act, announced today that it has completed a strategic investment of $1.5 million in Pharmastrip Corp. and signed a definitive collaboration and profit sharing agreement with the company, effective January 23, 2019. Under the terms of the agreement, FSD will install Pharmastrip proprietary equipment at its facility in Cobourg, Ontario.

  • FSD Pharma Announces Strategic Business Developments
    CNW Group15 days ago

    FSD Pharma Announces Strategic Business Developments

    TORONTO , Feb. 6, 2019 /CNW/ - FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD" or the "Company"), announced that its Board of Directors has concluded a strategic assessment of the Company and has implemented changes in leadership and business practices to optimize operations. Accordingly, the Company announced today that Dr. Raza Bokhari , Executive Co-Chairman, has been appointed interim Chief Executive Officer of FSD Pharma, effective immediately.

  • Newsfile15 days ago

    InvestmentPitch Media Video Discusses Licensed Cannabis Producer FSD Pharma's LOI with Solarvest BioEnergy to Develop and Test Production of Pharma-Grade Cannabinoids from Algae - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - February 6, 2019) -  FSD Pharma Inc. (CSE: HUGE) (FSE: 0K9) (OTCQB: FSDDF), a licensed cannabis producer, has signed a non-binding letter of intent with Solarvest BioEnergy Inc. to develop and test the production of pharma-grade cannabinoids from algae.Solarvest BioEnergy Inc. (TSXV:SVS), an algae technology company, has developed a platform capable of producing health products such as "Organic Omega 3 DHA" fruit gummies and food boosting powders, and has ...

  • GlobeNewswire15 days ago

    FSD Pharma Looks to Grow Cannabinoids in Algae -- CFN Media

    SEATTLE, Feb. 06, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article looking at what makes algae a unique platform for cannabinoid production, as well as how the new agreement with Solarvest fits into FSD Pharma’s plans to become a leading cannabis producer. FSD Pharma Inc. (CSE:HUGE) (FSDDF) (FRK:0K9) recently signed a letter of intent with Solarvest BioEnergy Inc. to apply Solarvest’s algae platform to develop pharmaceutical grade cannabinoids. The move could dramatically disrupt current cannabinoid procurement methods by reducing the time, space, and costs associated with cannabis cultivation, particularly for medical cannabis subject to GMP certification standards.

  • CNW Group16 days ago

    FSD Pharma Announces Signing of LOI with Solarvest to Develop and Test Pharma-Grade Cannabinoids out of Algae

    TORONTO , Feb. 5, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) ("FSD Pharma") and Solarvest BioEnergy Inc. (SVS.V) ("Solarvest") (collectively, the "Parties"), a technology company which has developed an algal-based flexible production platform capable of producing health products, are pleased to announce that they have signed a non-binding letter of intent ("LOI"). The parties intend to enter into a definitive agreement (the "Collaborative Research Agreement"), under which Solarvest would conduct research using its algal expression technology to develop pharma-grade cannabinoids (the "Project Cannabinoids"), the Parties would make mutual investments into one another, and Solarvest would grant FSD Pharma an exclusive license over a subset of the Project Cannabinoids and certain royalty rights over all of the other Project Cannabinoids.

  • FSD Pharma Congratulates High Tide Inc. for Signing LOI with Winner of Ontario Retail License Lottery to Operate Cannabis Retail Store
    CNW Group17 days ago

    FSD Pharma Congratulates High Tide Inc. for Signing LOI with Winner of Ontario Retail License Lottery to Operate Cannabis Retail Store

    TORONTO , Feb. 4, 2019 /CNW/ - FSD Pharma Inc. (HUGE.CN) (FSDDF) (FRA:OK9) ("FSD Pharma" or the "Company") would like to congratulate High Tide Inc. ("High Tide") for entering into a letter of intent with a winner of one of the 25 opportunities to apply for a license to operate a cannabis retail store (the "Winner") as a result of the Alcohol and Gaming Commission of Ontario's Expression of Interest Application Lottery conducted on January 11, 2019 . Under the terms of the LOI, High Tide will acquire a minority interest in the Winner and will assist the Winner with establishing and operating a cannabis retail store in Ontario . "The announcement today by our partners High Tide is exciting news.

  • Newsfile22 days ago

    CORRECTION FROM SOURCE: FSD Pharma Plans on Becoming the Largest Producer in the World, CEO Clip Video (new video)

    Vancouver, British Columbia--(Newsfile Corp. - January 30, 2019) - Rupert Haynes, CEO of FSD Pharma, speaks about pivoting from medical marijuana to a pharmaceutical company.If you cannot view the video above, please visit:https://www.b-tv.com/fsd-pharma-ceo-clips-90sec/FSD Pharma is being featured on BNN Bloomberg on Feb. 2 - Feb. 3, 2019, throughout the day and evenings.FSD Pharma (CSE: HUGE)fsdpharma.comAbout CEO Clips:CEO Clips is the largest library of publicly traded company CEO videos in Canada and the US. ...

  • GlobeNewswire24 days ago

    How Cannabinoids Could Replace Opioids -- CFN Media

    SEATTLE, Jan. 28, 2019 -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry,.

  • GlobeNewswirelast month

    FSD Pharma & Canntab Rank Among the Top 2018 Cannabis Stocks -- CFN Media

    SEATTLE, Jan. 17, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FSD Pharma Inc’s. (CSE:HUGE) (FSDDF) (0K9.F) & Canntab Therapeutics Ltd’s. (CSE:PILL) (TBF1.F) performance in 2018. The cannabis industry experienced significant growth last year, particularly in Canada following the legalization of adult-use cannabis on a federal level. The upcoming legalization of edible products across Canada could open the door to further growth in 2019 and beyond.

  • Newsfilelast month

    FSD Pharma, Plans for Becoming the Largest Producer in the World, CEO Clip Video

    Vancouver, British Columbia--(Newsfile Corp. - January 15, 2019) - Rupert Haynes, CEO of FSD Pharma speaks about pivoting from medical marijuana to a pharmaceutical company.If you cannot view the video above, please visit:https://www.b-tv.com/fsd-pharma-ceo-clips-90sec/FSD Pharma is being featured on BNN Bloomberg on Jan. 19 - Jan. 20, 2019, throughout the day and evenings.FSD Pharma (CSE: HUGE)fsdpharma.comAbout CEO Clips:CEO Clips is the largest library of publicly traded company CEO videos in Canada and the US. ...

  • Business Wirelast month

    FSD Pharma Congratulates Cannara Biotech for Its Listing and Commencement of Trading on the CSE

    FSD Pharma Inc. ("FSD" or the "Company") (HUGE.CN) (FSDDF) (0K9.F) would like to congratulate Cannara Biotech Inc. (“Cannara”) for its listing approval and commencement of trading on the Canadian Securities Exchange ("CSE") today under the stock symbol "LOVE". FSD Pharma, directly or indirectly, acquired ownership of 85,003,750 common shares ("Common Shares") of the Issuer, representing 12.25% of the issued and outstanding Common Shares of the Issuer. Anthony Durkacz, Co-Chairman of the Board and Co-Founder of FSD, said, "I want to congratulate Zohar Krivorot and his team at Cannara for achieving this significant milestone and for their ongoing efforts to build out the largest indoor cannabis grow facility in Quebec.

  • CNW Grouplast month

    FSD Pharma Announces Holdings in Cannara Biotech Inc.

    TORONTO , Jan. 11, 2019 /CNW/ - FSD Pharma ("FSD") announced today that, in connection with the business combination (the "Business Combination") completed on December 31, 2018 among Cannara Biotech Inc. (formerly, Dunbar Capital Corp.) (the "Issuer"), Cannara Biotech Inc. and 11038427 Canada Inc., FSD Pharma, directly or indirectly, acquired ownership of 85,003,750 common shares ("Common Shares") of the Issuer, representing 12.25% of the issued and outstanding Common Shares of the Issuer.

  • Business Wirelast month

    FSD Pharma Completes Harvest and Passes Analytical Testing of Second Lot

    FSD Pharma Inc. (“FSD Pharma” or the “Company”) (HUGE.CN) (FSDDF) (0K9.F) is pleased to announce that its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”), a licensed cannabis producer under the Cannabis Act, has completed the harvest of its second lot of cannabis and successfully passed all analytical testing, thereby positioning the Company to request a Pre-Sales License Inspection from Health Canada. The Pre-Sales License Inspection is the last step prior to the issuance of a Sales License under the Cannabis Act and Regulations.